FORMULATION AND EVALUATION OF CEFUROXIME AXETIL GRANULES FOR ORAL SUSPENSION
DOI:
https://doi.org/10.22159/ajpcr.2023.v16i7.47397Keywords:
Cefuroxime Axetil, Granulation, Dry Suspension, BioavailabilityAbstract
Objectives: The aim of this study is formulation and evaluation of cefuroxime axetil (CA) granules for oral suspension and to compare its in vitro bioavailability with Innovator Product.
Methods: The granules of CA were prepared by wet granulation method. Six formulations of varying composition of ingredients were prepared. Preformulation studies were performed. The suspension was evaluated for its flow property, in vitro dissolution study, and assay.
Results: Preformulation parameters show that the flow property of powder is poor. The suspension was successfully prepared by wet granulation method. The flow property of granules varied form fair to excellent in different formulations. The f2value ranges from 25 to 77.
Conclusion: With a better release characteristic and excellent flow property, the formulation F6 is considered as the final formulation with an f2 value of 77 and assay of 99.7%.
Downloads
References
Powell DA, James NC, Ossi MJ, Nahata MC, Donn KH. Pharmacokinetics of cefuroxime axetil suspension in infants and children. Antimicrob Agents Chemother 1991;35:2042-5. doi: 10.1128/ AAC.35.10.2042, PMID 1759825
Ivana I, Ljiljana Z, Mira Z. A stability indicating assay method for cefuroxime axetil and its application to analysis of tablets exposed to accelerated stability test conditions. J Chromatogr A 2006;1119:209-15. doi: 10.1016/j.chroma.2005.12.079, PMID 16445930
Emmerson AM. Cefuroxime axetil. J Antimicrob Chemother 1988;22:101-4. doi: 10.1093/jac/22.2.101, PMID 3053551
Ridgway E, Stewart K, Rai G, Kelsey MC, Bielawska C. The pharmacokinetics of cefuroxime axetil in the sick elderly patient. J Antimicrob Chemother 1991;27:663-8. doi: 10.1093/jac/27.5.663, PMID 1885424
Ruiz-Balaguer N, Nacher A, Casabo VG, Sanjuan MM. Intestinal transport of cefuroxime axetil in rats: Absorption and hydrolysis processes. Int J Pharm 2002;234:101-11. doi: 10.1016/s0378- 5173(01)00956-5, PMID 11839441
Douroumis D. Practical approaches of taste masking technologies in oral solid forms. Expert Opin Drug Deliv 2007;4:417-26. doi: 10.1517/17425247.4.4.417, PMID 17683254
Sohi H, Sultana Y, Khar RK. Taste masking technologies in oral pharmaceuticals: Recent developments and approaches. Drug Dev Ind Pharm 2004;30:429-48. doi: 10.1081/ddc-120037477, PMID 15244079
Chivate A, Sargar V, Nalawade P, Tawde V. Formulation and development of oral dry suspension using taste masked Ornidazole particles prepared using Kollicoat Smartseal 30 D. Drug Dev Ind Pharm 2013;39:1091-7.
Lieberman HA, Lachman L, Schwartz JB. Pharmaceutical Dosage Forms: Tablets. Vol. 1. United States: CRC Press; 1989.
Martin A, Bustamate P, Chun AH. Physical Pharmacy: Physical Chemical Principles in the Pharmaceutical Sciences. Vol. 4. Philadelphia, PA: Lea and Febiger; 1993. p. 284-323.
Arora SC, Sharma PK, Irchhaiya R, Khatkar A, Singh N, Gagoria J. Development, characterization and solubility study of solid dispersions of cefuroxime axetil by the solvent evaporation method. J Adv Pharm Technol Res 2010;1:326-9. doi: 10.4103/0110-5558.72427, PMID 22247865
Mader WJ, Higuchi T. Phase solubility analysis. CRC Crit Rev Anal Chem 1970;1:193-215. doi: 10.1080/10408347008542734
Sruti J, Patra CN, Swain S, Panigrahi KC, Patro AP, Beg S, et al. Improvement in the dissolution rate and tableting properties of cefuroxime axetil by melt-granulated dispersion and surface adsorption. Acta Pharm Sin B 2013;3:113-22. doi: 10.1016/j.apsb.2013.01.001
Amir SB, Hossain MA, Mazid MA. Development and validation of UV spectrophotometric method for the determination of cefuroxime axetil in bulk and pharmaceutical formulation. J Sci Res 2013;6:133-41.
USP. NF Cefuroxime Axetil. United States Pharmacopoeia Natl Formul (USP- 40- NF- 35). Vol. 335. United States. Rockville, MD: US Pharmacopeial Convention Inc.; 2000.
Published
How to Cite
Issue
Section
Copyright (c) 2023 Aditya Jaitly, Rahul Sharma, Rizwan Zafar
This work is licensed under a Creative Commons Attribution 4.0 International License.
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.
